Compounds > morinidazole
Page last updated: 2024-08-02 21:24:08

morinidazole

Description

morinidazole: structure in first source [MeSH]

Cross-References

ID SourceID
PubMed CID11644726
CHEMBL ID3884248
MeSH IDM0543964

Synonyms (22)

Synonym
CS-5058
unii-tupwg40jal
morinidazole
HY-15781
NCGC00485480-01
morponidazole [inn]
morponidazole
(+/-)-1-(2-methyl-5-nitro-1h-imidazol-1-yl)-3-morpholinopropan-2-ol
morinidazole [who-dd]
TUPWG40JAL ,
92478-27-8
CHEMBL3884248
Z1516471620
DB15098
1-(2-methyl-5-nitro-1h-imidazol-1-yl)-3-morpholinopropan-2-ol
F85285
MS-23827
1-(2-methyl-5-nitroimidazol-1-yl)-3-morpholin-4-ylpropan-2-ol
DTXSID201031280
1-(2-methyl-5-nitro-1h-imidazol-1-yl)-3-(morpholin-4-yl)propan-2-ol
EN300-6504759
AKOS040733770

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560		Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1335738Antiparasitic activity against metronidazole sensitive Trichomonas vaginalis ATCC 33592 after 48 hrs by trypan blue exclusion assay2016European journal of medicinal chemistry, Nov-29, Volume: 124ISSN: 1768-32542-Methyl-4/5-nitroimidazole derivatives potentiated against sexually transmitted Trichomonas: Design, synthesis, biology and 3D-QSAR study.
AID1335752Potency index, ratio of metronidazole MIC to compound MIC for metronidazole resistant Trichomonas vaginalis ATCC 501432016European journal of medicinal chemistry, Nov-29, Volume: 124ISSN: 1768-32542-Methyl-4/5-nitroimidazole derivatives potentiated against sexually transmitted Trichomonas: Design, synthesis, biology and 3D-QSAR study.
AID1335740Cytotoxicity against human HeLa cells after 24 hrs by MTT assay2016European journal of medicinal chemistry, Nov-29, Volume: 124ISSN: 1768-32542-Methyl-4/5-nitroimidazole derivatives potentiated against sexually transmitted Trichomonas: Design, synthesis, biology and 3D-QSAR study.
AID1335739Antiparasitic activity against metronidazole resistant Trichomonas vaginalis ATCC 50143 after 48 hrs by trypan blue exclusion assay2016European journal of medicinal chemistry, Nov-29, Volume: 124ISSN: 1768-32542-Methyl-4/5-nitroimidazole derivatives potentiated against sexually transmitted Trichomonas: Design, synthesis, biology and 3D-QSAR study.
AID1335742Selectivity index, ratio of IC50 for human HeLa cells to MIC for metronidazole resistant Trichomonas vaginalis ATCC 501432016European journal of medicinal chemistry, Nov-29, Volume: 124ISSN: 1768-32542-Methyl-4/5-nitroimidazole derivatives potentiated against sexually transmitted Trichomonas: Design, synthesis, biology and 3D-QSAR study.
AID1335741Selectivity index, ratio of IC50 for human HeLa cells to MIC for metronidazole sensitive Trichomonas vaginalis ATCC 335922016European journal of medicinal chemistry, Nov-29, Volume: 124ISSN: 1768-32542-Methyl-4/5-nitroimidazole derivatives potentiated against sexually transmitted Trichomonas: Design, synthesis, biology and 3D-QSAR study.

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's13 (81.25)24.3611
2020's3 (18.75)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (25.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (75.00%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
metronidazole
1
C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic		201620168.0low000010
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
formic acid
1
monocarboxylic acidantibacterial agent;
astringent;
metabolite;
protic solvent;
solvent		2010201014.0low000100
cimetidine
1
aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor		2014201410.0low000010
fluconazole
1
conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic		2014201410.0low000010
ketoconazole
1
dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine		2014201410.0low000010
metronidazole
2
C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic		2010201213.0low000110
probenecid
1
benzoic acids;
sulfonamide		uricosuric drug2014201410.0low000010
tinidazole
1
imidazolesantiamoebic agent;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug		2012201212.0low000010
morpholine
1
morpholines;
saturated organic heteromonocyclic parent		NMR chemical shift reference compound2012201212.0low000010
azomycin
12
C-nitro compound;
imidazoles		antitubercular agent2010202010.3high4001110
methyl tert-butyl ether
1
etherfuel additive;
metabolite;
non-polar solvent		2014201410.0low000010
ornidazole
2
C-nitro compound;
imidazoles;
organochlorine compound;
secondary alcohol		antiamoebic agent;
antibacterial drug;
antiinfective agent;
antiprotozoal drug;
antitrichomonal drug;
epitope		201220179.5low100020
tenofovir
1
nucleoside analogue;
phosphonic acids		antiviral drug;
drug metabolite;
HIV-1 reverse transcriptase inhibitor		202020204.0low100010
warfarin
1
benzenes;
hydroxycoumarin;
methyl ketone		2012201212.0low000010
rifampin
1
cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor		2014201410.0low000010
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Adnexitis0
1
201720177.0low100010
Adverse Drug Event0
1
201720177.0low100010
Candida Infection0
1
2014201410.0low000010
Candidiasis0
1
2014201410.0low000010
Congenital Zika Syndrome0
1
202020204.0low000010
Disease Models, Animal0
1
202020204.0low000010
Drug-Related Side Effects and Adverse Reactions0
1
201720177.0low100010
Kidney Failure0
4
2012201410.8medium200040
Parodontosis0
1
2012201212.0low000010
Pelvic Inflammatory Disease0
1
201720177.0low100010
Periodontal Diseases0
1
2012201212.0low000010
Renal Insufficiency0
4
2012201410.8medium200040
Sensitivity and Specificity0
1
2012201212.0low000010
Sexually Transmitted Diseases0
1
201620168.0low000010
Viral Diseases0
1
201720177.0low100010
Virus Diseases0
1
201720177.0low100010
Zika Virus Infection0
1
202020204.0low000010

Safety/Toxicity (1)

ArticleYear
Efficacy and safety of morinidazole in pelvic inflammatory disease: results of a multicenter, double-blind, randomized trial.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, , Volume: 36, Issue:7		2017

Pharmacokinetics (5)

ArticleYear
Effects of rifampin and ketoconazole on pharmacokinetics of morinidazole in healthy chinese subjects.
Antimicrobial agents and chemotherapy, , Volume: 58, Issue:10		2014
Effects of renal impairment on the pharmacokinetics of morinidazole: uptake transporter-mediated renal clearance of the conjugated metabolites.
Antimicrobial agents and chemotherapy, , Volume: 58, Issue:7		2014
Pharmacokinetics of single-dose morinidazole in patients with severe renal impairment.
International journal of clinical pharmacology and therapeutics, , Volume: 52, Issue:2		2014
Simultaneous determination of morinidazole and its carbonylation metabolite in human plasma: application to a pharmacokinetic study involving renal insufficiency patients and healthy volunteers.
Journal of pharmaceutical and biomedical analysis, , Mar-25, Volume: 76		2013
Metabolism and pharmacokinetics of morinidazole in humans: identification of diastereoisomeric morpholine N+-glucuronides catalyzed by UDP glucuronosyltransferase 1A9.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:3		2012

Bioavailability (1)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5		2019

Interactions (1)

ArticleYear
[Enantioselective determinination of R-warfarin/S-warfarin in human plasma using liquid chromatography-tandem mass spectrometry and its application in a drug-drug interaction study].
Yao xue xue bao = Acta pharmaceutica Sinica, , Volume: 47, Issue:1		2012